Articles Vol. 65 No. CĐ10 - Bệnh viện Thống Nhất 30/10/2024

35. CHARACTERISTICS OF MOLECULAR SUBTYPES OF BREAST CANCER AT THONG NHAT HOSPITAL

Nguyen Thi Mai Huong1,2, Ha Kieu Trang3,4, Tran Huynh Hanh Thao1,2, Phan Dang Anh Thu1,2,3,4
1 Thong Nhat Hospital
2 Bệnh viện Thống Nhất
3 University of Medicine and Pharmacy at Ho Chi Minh City
4 Trường Đại học Y Dược Thành phố Hồ Chí Minh
Corresponding author: phandanganhthu@ump.edu.vn
DOI: 10.52163/yhc.v65iCD10.1623
25 Views
17 Downloads
Keywords
Invasive breast carcinoma immunohistochemistry molecular subtype HER2 ER PR Ki67
Abstract

Introduction: A comprehensive understanding of the molecular characteristics of breast cancer is crucial for the development of more effective diagnostic and therapeutic strategies. Molecular classification of breast cancer provides valuable insights that can guide treatment decisions.

Methods: This study involved a cross-sectional description of invasive breast carcinoma cases treated at Thong Nhat Hospital in 2023. Histopathological evaluation and molecular subtyping were performed based on immunohistochemistry of ER, PR, HER2, and Ki-67 markers.

Results: In our 2023 study of 49 cases of breast carcinoma at Thong Nhat Hospital, the following distribution was observed: Luminal B subtype predominates with a rate of 55.1%. Luminal A subtype accounted for 28.6%. Triple-negative subtype: 8.2% HER2 subtype: 8.2%. Statistical analysis revealed a significant correlation between molecular subtype characteristics and the Ki-67 proliferation index (p<0.001). Triple-negative and HER2 subtypes exhibited a high Ki-67 mitotic index. No significant association was found between molecular subtypes and patient age or histological grade.

Conclusion: The molecular subtyping of breast cancer plays a crucial role in selecting precise and personalized treatment methods for each patient. Personalized treatment includes endocrine therapy and may consider adding neoadjuvant chemotherapy or targeted drugs to achieve the best treatment outcomes for the patient.

References
[1]
Gulzar, R., Shahid, R., & Saleem, O. (2018). Molecular subtypes of breast cancer by immunohistochemical profiling. Int J Pathol, 16(2), 129-134. Google Scholar
[2]
Park, S., Koo, J. S., Kim, M. S., Park, H. S., Lee, J. S., Lee, J. S., ... & Park, B. W. (2012). Characteristics and outcomes according to molecular subtypes of breast cancer as classified by a panel of four biomarkers using immunohistochemistry. The Breast, 21(1), 50-57. Google Scholar
[3]
Zhao, S., Ma, D., Xiao, Y., Jiang, Y. Z., & Shao, Z. M. (2018). Clinicopathologic features and prognoses of different histologic types of triple-negative breast cancer: a large population-based analysis. European Journal of Surgical Oncology, 44(4), 420-428. Google Scholar
[4]
Pruneri, G., Gray, K. P., Vingiani, A., Viale, G., Curigliano, G., Criscitiello, C., ... & Colleoni, M. (2016). Tumor-infiltrating lymphocytes (TILs) are a powerful prognostic marker in patients with triple-negative breast cancer enrolled in the IBCSG phase III randomized clinical trial 22-00. Breast cancer research and treatment, 158(2), 323-331. Google Scholar
[5]
Carey, L. A., Dees, E. C., Sawyer, L. R., Gatti, L., Moore, D., Collichio, F., ... & Perou, C. M. (2004, January). The triple negative paradox: primary tumor chemosensitivity of the basal-like breast cancer (BBC) phenotype. In BREAST CANCER RESEARCH AND TREATMENT (Vol. 88, pp. S48-S49). 233 SPRING STREET, NEW YORK, NY 10013 USA: SPRINGER. Google Scholar
[6]
Kornegoor, R., Verschuur-Maes, A. H., Buerger, H., Hogenes, M. C., De Bruin, P. C., Oudejans, J. J., ... & Van Diest, P. J. (2012). Molecular subtyping of male breast cancer by immunohistochemistry. Modern Pathology, 25(3), 398-404. Google Scholar
[7]
Rashmi, S., Kamala, S., Murthy, S. S., Kotha, S., Rao, Y. S., & Chaudhary, K. V. (2018). Predicting the molecular subtype of breast cancer based on mammography and ultrasound findings. Indian Journal of Radiology and imaging, 28(03), 354-361. Google Scholar
[8]
Nguyễn Thị Tuyền (2023), Đặc điểm mô bệnh học ung thư vú có bộ ba dấu ấn hóa mô miễn dịch âm tính tại Bệnh viện ung bướu Đà Nẵng, Tạp chí y dược học Cần Thơ – số 58/2023. Google Scholar
[9]
Nguyễn Văn Chủ (2017), Nghiên cứu áp dụng phân loại phân tử ung thư biểu mô tuyến vú bằng phương pháp hóa mô miễn dịch, Đại học Y Hà Nội. Google Scholar
[10]
Đoàn Thị Phương Thảo. Nghiên cứu gen HER2 và phân nhóm phân tử ung thư vú. Đề tài tiến sĩ y học. Trường Đại học Y Dược Thành phố Hồ Chí Minh. 2012. Google Scholar
[11]
Lê Phong (2021), Nghiên cứu đặc điểm phân nhóm phân tử ung thư biểu mô tuyến vú bằng kỹ thuật hóa mô miễn dịch trên bệnh nhân ung thư biểu mô tuyến vú xâm lấn tại Bệnh viện ung bướu Thành phố Cần Thơ năm 2021-2022, Tạp chí y dược học Cần Thơ – số 61/2023. Google Scholar
[12]
Sotiriou, C., Neo, S. Y., McShane, L. M., Korn, E. L., Long, P. M., Jazaeri, A., ... & Liu, E. T. (2003). Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proceedings of the National Academy of Sciences, 100(18), 10393-10398. Google Scholar
[13]
Millikan, R. C., Newman, B., Tse, C. K., Moorman, P. G., Conway, K., Smith, L. V., ... & Perou, C. M. (2008). Epidemiology of basal-like breast cancer. Breast cancer research and treatment, 109, 123-139. Google Scholar
[14]
Cheang, M. C., Chia, S. K., Voduc, D., Gao, D., Leung, S., Snider, J., ... & Nielsen, T. O. (2009). Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. JNCI: Journal of the National Cancer Institute, 101(10), 736-750. Google Scholar
[15]
Hicks, D. G., Short, S. M., Prescott, N. L., Tarr, S. M., Coleman, K. A., Yoder, B. J., ... & Weil, R. J. (2006). Breast cancers with brain metastases are more likely to be estrogen receptor negative, express the basal cytokeratin CK5/6, and overexpress HER2 or EGFR. The American journal of surgical pathology, 30(9), 1097-1104. Google Scholar
[16]
Adly, S., Hewedi, I. H., & Mokhtar, N. M. (2010). Clinicopathologic significance of molecular classification of breast cancer: relation to nottingham prognosis index. Journal of the Egyptian National Cancer Institute, 22(4), 209-215. Google Scholar
[17]
Rouzier, R., Perou, C. M., Symmans, W. F., Ibrahim, N., Cristofanilli, M., Anderson, K., ... & Pusztai, L. (2005). Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clinical cancer research, 11(16), 5678-5685. Google Scholar
[18]
Coates, A. S., Winer, E. P., Goldhirsch, A., Gelber, R. D., Gnant, M., Piccart-Gebhart, M., ... & Xu, B. (2015). Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015. Annals of oncology, 26(8), 1533-1546. Google Scholar
[19]
Ahmad Fauzi, M. F., Wan Ahmad, W. S. H. M., Jamaluddin, M. F., Lee, J. T. H., Khor, S. Y., Looi, L. M., ... & Aldahoul, N. (2022). Allred scoring of ER-IHC stained whole-slide images for hormone receptor status in breast carcinoma. Diagnostics, 12(12), 3093. Google Scholar